Marker for diagnosing tuberculosis infection and use thereof
By using chemokines such as CXCL9, CXCL10 and CCL8 as biomarkers, the problem of localization of IFN-γ detection in the prior art is solved, the diagnostic sensitivity and specificity of tuberculosis infection are improved, and early diagnosis of tuberculosis and New approaches to evaluation of treatment effects.
Patent Information
- Application Number
- PCT/CN2023/098746
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2023-06-07
- Publication Date
- 2024-11-28
Smart Images

Figure CN2023098746_28112024_PF_FP_ABST
Abstract
Description
A marker for diagnosing tuberculosis infection and its application Technical Field
[0001] The present invention relates to the technical field of medicine, and relates to a marker for diagnosing tuberculosis infection and application thereof. Background Art
[0002] Tuberculosis (TB) is a chronic infectious disease caused by infection with Mycobacterium tuberculosis. It has become one of the leading causes of death among adults worldwide due to infectious diseases. It is highly contagious, has a high recurrence rate, and can easily develop into multidrug-resistant TB, making it more difficult to treat. Therefore, early diagnosis and treatment are key to controlling the spread of TB.
[0003] Currently, clinical TB diagnosis primarily relies on etiological, molecular, and immunological methods. Etiological methods primarily include smear and bacterial culture. The smear method is simple and rapid, but suffers from low sensitivity and a long bacterial culture cycle, making it difficult to diagnose TB early. Molecular biological diagnosis focuses on nucleic acid amplification techniques, such as Xpert Mtb / RIF, liquid amplification (LAMP), and polymerase chain reaction (PCR). Immunological diagnostic methods, primarily interferon-gamma release assays (IGRAs), have advanced TB diagnosis and have been used to some extent in clinical practice. The detection principle is that after the human body is infected with Mycobacterium tuberculosis, memory T lymphocytes are produced. When specific tuberculosis antigens invade again, these memory cells rapidly proliferate and activate to form a large number of effector T lymphocytes, which release gamma interferon (IFN-γ) and other cytokines. Further detection using enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunospot assay (ELISPOT) can determine whether the body is infected with Mycobacterium tuberculosis. In recent years, IGRAs have been widely used in the diagnosis of tuberculosis. They have good sensitivity and specificity, which can improve the diagnosis rate of the disease.
[0004] Currently, immune responses primarily detected by IFN-γ, while highly sensitive, also have limitations. Clinical studies have shown that due to variations in immune responses among tuberculosis patients, approximately 10-15% of tuberculosis patients test negative for IGRAs. When peripheral blood mononuclear cells are stimulated by tuberculosis-specific antigens, they release a variety of inflammatory markers. The release of these inflammatory markers is associated with the body's immune response against tuberculosis infection and ultimately leads to different outcomes of tuberculosis infection. Therefore, it is clinically desirable to identify diagnostic markers beyond IFN-γ to improve diagnostic sensitivity. With the development of Luminex suspension chip technology, multiple biomarkers can be detected and screened simultaneously, providing a reference for the clinical diagnosis and treatment of tuberculosis.
[0005] Patent CN113748342A discloses the use of a combination of biomarkers IFNγ, IL-10, CD120b and CD14 for diagnosing active mycobacterial infection and / or monitoring the progression of active mycobacterial infection, for diagnosing active mycobacterial infection and / or monitoring the progression of active mycobacterial infection or for diagnosing the absence of mycobacterial infection, in particular tuberculosis.
[0006] Chemokines are a family of highly conserved proteins (relative molecular mass 8000-12000) that participate in many biological processes, including chemotactic cell migration, immune cell degranulation, hematopoiesis, and angiogenesis (Miller MC, Mayo KH. Chemokines from a Structural Perspective. Int J Mol Sci, 2017, 18(10): 2088. doi: 10.3390 / iims18102088.). Chemokines are generally divided into three subfamilies based on the sequential positioning of their highly conserved cysteine residues: CC motif (CC) chemokines, CXC motif (CXC) chemokines, and C-X3-C motif (CX3C) chemokines. The biological functions of chemokines are mostly classified as inflammatory factors. They play a key role in controlling the recruitment of immune cells in inflammatory reactions, that is, chemokines play an important role in organizing immune responses (Zlotnik A, Yoshie O. The chemokine superfamily revisited Immunit, 2012, 36(5): 705-716 doi: 10.1016 / j.immuni.2012.05.008.). Li Youlun et al. believe that chemokines bind to receptors on their corresponding target cells in the human body and activate corresponding signaling pathways by inducing the dissociation of the BY subunit of the G protein to exert their biological functions. Different types of chemokines have different functions. CC chemokines mainly chemotactic monocytes, CXC chemokines mainly chemotactic neutrophils, C chemokines can chemotactic lymphocytes, and the CX3C subfamily is mainly involved in the migration and activation of giant cells and lymphocytes. In addition, chemokines play a role in the MTB infection process, being crucial for recruiting and coordinating the entry of immune cells into the MTB-infected lungs. Monocyte recruitment and localization can effectively control bacterial growth and prevent the development of diffuse granulocytic inflammation. For example, interferon-induced protein 10 (IP-10 / CXCL10) can mediate the migration and activation of immune cells in the human body by binding to receptors on target cells, playing a crucial role in anti-TB immunity. However, certain chemokines and cytokines exacerbate the spread of infection and tissue damage, exerting a dual effect on the anti-MTB infection process. Under certain conditions, chemokines can also cause disproportionate inflammation and lung damage, thereby accelerating the progression of lung disease and cavitation.
[0007] The present invention provides a group of specific biomarkers for diagnosing infection with the pathogen Mycobacterium tuberculosis.
[0008] Summary of the Invention
[0009] In a first aspect, the present invention provides a biomarker for diagnosing tuberculosis infection, wherein the marker is one or more of CXCL9, CXCL10, and CCL8. When the expression level of one or more of CXCL9, CXCL10, and CCL8 is higher than the critical value of the factor expression level, the subject can be diagnosed as being infected with Mycobacterium tuberculosis; when the expression level of one or more of CXCL9, CXCL10, and CCL8 is lower than or equal to the critical value of the factor expression level, the subject can be diagnosed as being infected with non-tuberculosis mycobacteria.
[0010] Furthermore, the critical expression values (pg / mL) of CXCL9, CXCL10, and CCL8 were 258.78, 267.53, and 30.31, respectively.
[0011] Furthermore, the tuberculosis infection is an infection caused by the presence of the pathogen Mycobacterium tuberculosis.
[0012] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, and extrapulmonary infection.
[0013] In a second aspect, the present invention provides a method for evaluating the efficacy of a treatment for tuberculosis infection, comprising:
[0014] S1 obtains a test biological sample from a tuberculosis-infected person;
[0015] S2 detects the levels of biomarkers such as CXCL9, CXCL10, and CCL8;
[0016] S3 compares the detection results of the CXCL9, CXCL10, and CCL8 contents with their corresponding critical values. When the expression levels of one or more of CXCL9, CXCL10, CCL8, and the combination of CXCL10 and CCL8 are respectively higher than the critical value of the factor, the subject can be diagnosed as being infected with Mycobacterium tuberculosis, indicating that the anti-tuberculosis infection treatment for the subject is poor or ineffective; when the expression levels of one or more of CXCL9, CXCL10, CCL8, and the combination of CXCL10 and CCL8 are respectively lower than or equal to the critical value of the factor, the subject can be diagnosed as being infected with non-tuberculosis mycobacteria, indicating that the anti-tuberculosis infection treatment for the subject is effective.
[0017] Furthermore, the biological sample may be tissue fluid or blood.
[0018] Furthermore, the critical expression values (pg / mL) of CXCL9, CXCL10, and CCL8 were 258.78, 267.53, and 30.31, respectively.
[0019] In a third aspect, the present invention provides a kit for diagnosing tuberculosis infection, wherein the kit contains reagents for detecting biomarkers, instructions, etc., wherein the markers are one or more of CXCL9, CXCL10, and CCL8.
[0020] In a fourth aspect, the present invention provides a use of a biomarker in the preparation of a preparation for diagnosing tuberculosis infection.
[0021] Furthermore, the biomarkers are one or more of CXCL9, CXCL10, and CCL8.
[0022] Furthermore, when the expression levels of one or more of CXCL9, CXCL10, and CCL8 are higher than the critical value of the expression level of the factor, the subject can be diagnosed as being infected with Mycobacterium tuberculosis; when the expression levels of one or more of CXCL9, CXCL10, and CCL8 are lower than or equal to the critical value of the expression level of the factor, the subject can be diagnosed as being infected with non-tuberculosis mycobacteria.
[0023] Furthermore, the critical expression values (pg / mL) of CXCL9, CXCL10, and CCL8 were 258.78, 267.53, and 30.31, respectively. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 shows the chemokine expression levels of peripheral blood mononuclear cells from healthy controls (HC), latently infected individuals (LTBI), IGRA-positive tuberculosis patients (TB IGRA+) and IGRA-negative tuberculosis patients (TB IGRA-) after stimulation with tuberculosis antigens.
[0025] FIG2 is a ROC curve analysis diagram of MIG / CXCL9.
[0026] FIG3 is a ROC curve analysis diagram of IP-10 / CXCL10.
[0027] FIG4 is a ROC curve analysis diagram of MCP-2 / CCL8.
[0028] FIG5 is a ROC curve analysis diagram of the IP-10 / CXCL10 and MCP-2 / CCL8 combinations. DETAILED DESCRIPTION
[0029] The following is a further description of specific embodiments of the present invention. It should be noted that the description of these embodiments is intended to facilitate understanding of the present invention and does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
[0030] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0031] The "CXCL9" mentioned in this article is the chemokine interferon-γ induced monokine (MIG), which belongs to the CXC family of chemokines. It is mainly produced by macrophages stimulated by IFN-γ in the body. Its structural characteristics are a precursor protein sequence with 125 amino acids and a signal peptide sequence containing 21 amino acids. Compared with other chemokines, it contains more than 50% basic amino acids, so its molecular weight is larger than most other chemokines. The hydroxyl end of CXCL9 is easily hydrolyzed and broken, resulting in a certain difference in the size of natural and recombinant CXCL9. CXCL9 plays a key role in leukocyte trafficking and acts on activated CD4 + Th1 cells, CD8 + T cells, IL-2 activated T lymphocytes and NK cells. After the receptor CXCR3 is activated, it can be rapidly induced to produce and in the Th1 type CD4 + T cells and effector CD8 + CXCL9 is highly expressed in T cells such as NK cells and NKT cells. Therefore, it plays an important role in many diseases, including external infections, tumor treatment, autoimmune diseases, and transplant rejection.
[0032] The "CXCL10" mentioned herein refers to CXC motif chemokine 10 (CXCL10), also known as interferon gamma-induced protein 10 (IP-10) or small inducible cytokine B10. CXCL10 is an 8.7kDa protein that is encoded by the CXCL10 gene in humans. CXCL10 is a small cytokine belonging to the CXC chemokine family and can be produced by neutrophils, monocytes, eosinophils, epithelial cells, endothelial cells, stromal cells, etc. after induction by IEN-Y. IP-10 exerts its effect by binding to the chemokine receptor CXCR3, recruiting a variety of CXCR3* cells to lymph nodes or local tissue activated T cells, helper T cells, Tregs, plasmacytoid dendritic cells (pDC), monocytes, and NK cells.
[0033] The "CCL8" mentioned in this article, also known as monocyte chemoattractant protein-2 (MCP-2), is a key member of the CC family of chemokines. It plays a crucial role in B cell and mitochondrial maturation and T cell differentiation, participating in both Th1 and Th2 immune responses. Therefore, CCL8 plays a crucial immunomodulatory role in inflammatory responses, immune responses, and tumor immunity. Chemokines are a large class of low molecular weight proteins with highly homologous three-dimensional structures. They were originally discovered for their role in guiding leukocyte migration and proliferation. The chemokine family has 27 members, of which chemokines are a subfamily and are a crucial component of intercellular communication. Chemokines can produce biological effects by binding to seven-transmembrane G protein-coupled receptors (GPCRs). Chemokines are generally divided into four families based on the configuration of their N-terminal cysteine residues: CC, CXC, CX3C, and XC. CCL8 is a member of the CC chemokine family, and its encoding gene is one of several chemokine genes clustered on the q arm of chromosome 17. CCL8 participates in immune regulation and inflammatory responses. Its structure is essentially identical to other members of the CC chemokine family, sharing a common structural characteristic of the CC family: two vicinal disulfide bonds formed by four cysteine residues within its amino acid structure. The CCL8 precursor protein consists of 109 amino acids, while the mature CCL8 protein consists of 75 amino acids.
[0034] References herein to "tuberculosis infection" include infection caused by the presence of the pathogen Mycobacterium tuberculosis, and references to persons infected with tuberculosis include references to IGRA-positive tuberculosis patients (TB IGRA+), IGRA-negative tuberculosis patients, and latent asymptomatic tuberculosis infection (LTBI).
[0035] As described in this article: Sensitivity = true positive value / (true positive value + false negative value); Specificity = true negative value / (true negative value + false positive value); Positive likelihood ratio = true positive value / (true positive value + false positive value); Negative likelihood ratio = true negative value / (true negative value + false negative value); Accuracy = (true positive value + true negative value) / (true positive value + true negative value + false negative value + false positive value); Among them, a false positive can refer to the result of misjudging a patient who does not have tuberculosis as a positive for various reasons, and a false negative is the result of misjudging a patient with tuberculosis as not having tuberculosis.
[0036] Example 1 Screening Method for Biomarkers for Diagnosing Tuberculosis Infection
[0037] 1.1 Case collection
[0038] Specimens were collected from subjects, including healthy controls (HC), latent tuberculosis infection (LTBI), IGRA-positive tuberculosis patients (TB IGRA+), and IGRA-negative tuberculosis patients (TB IGRA-).
[0039] 1.1.1 Active pulmonary tuberculosis refers to patients with clinical symptoms of tuberculosis, confirmed by sputum acid-fast bacilli smear or culture, pathological confirmation or sputum molecular biology confirmation, including IGRA-positive and -negative tuberculosis.
[0040] 1.1.2 Inclusion criteria for latently infected patients: high risk factors for tuberculosis infection, positive tuberculosis-specific IGRA test, and no evidence of tuberculosis infection on chest radiograph;
[0041] 1.1.3 Healthy controls: no high-risk factors for tuberculosis infection and no obvious abnormalities on chest X-ray.
[0042] The above populations were excluded from patients with tumors, those taking immunomodulatory drugs, HIV infection and other autoimmune diseases.
[0043] 1.2 Stimulation of peripheral blood cells with Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10
[0044] 1.2.1 Sample Collection: 4 mL of peripheral blood was collected from each subject in the morning on an empty stomach and placed in a blood collection tube containing sodium heparin for anticoagulation. The blood was then added to a cell stimulation culture tube for stimulation culture within 6 hours of collection. The blood was not allowed to be frozen or centrifuged.
[0045] 1.2.2 Sample packaging: Gently mix the blood collection tube by inverting it upside down 8 times, draw 0.6 mL of fresh human venous anticoagulated blood from each tube, add it to the cell stimulation culture tube (N, T, P), and mix the culture tube by inverting it upside down 5 times.
[0046] 1.2.3 Culture: Place the cell stimulation culture tube in a constant temperature incubator at 37±0.5℃ for 20±2h. Keep the culture tube upright during the culture process.
[0047] 1.2.4 Separation: After incubation, the culture tubes can be centrifuged (1000 g, 5 min) or other methods to separate the plasma.
[0048] 1.3 Liquid suspension chip technology detection
[0049] Plasma stimulated with specific antigens from four groups of patients (healthy controls, latently infected individuals, IRGA-positive TB patients, and IRGA-negative TB patients) was assayed for chemokines or cytokines using the Bio-Plex Pro Human Chemokine Panel 40-plex kit. The specific steps are as follows:
[0050] 1.3.1 Sample preparation
[0051] Cell culture plasma: Centrifuge at 10,000 rpm for 10 minutes, take the supernatant, dilute 4-fold with Sample Diluent, and finally take 50 μL of the diluted sample for detection.
[0052] 1.3.2 Preparation of Standards
[0053] Add 781 μL of StandardDiluent to the standard bottle, vortex for 5 seconds, and place on ice for 30 minutes. Dilute the standard in series according to the instructions.
[0054] 1.3.3 Sample incubation
[0055] (1) Oscillate the beads on an oscillator at 1400 rpm for 30 seconds and dilute the beads with Assay Buffer.
[0056] (2) The diluted beads were shaken again at 1400 rpm for 30 s, 50 μL per well was added to a 96-well plate, and washed three times using a plate washer;
[0057] (3) Take 50 μL of the prepared standard, sample, reference and Blank and add them to a 96-well plate. Cover with sealing film and place on a plate shaker at 850 rpm. Incubate at room temperature for 1 h in the dark.
[0058] 1.3.4 Incubation with detection antibodies
[0059] (1) Discard the sample and wash three times using a plate washer;
[0060] (2) Use Antibody Diluent to dilute Detection Antibody according to the instructions;
[0061] (3) Add 25 μL of diluted DetectionAntibody to each well, cover with sealing film, place on a plate shaker at 850 rpm, protect from light, incubate at room temperature for 30 minutes.
[0062] 1.3.5 Color Rendering
[0063] (1) Discard the detection antibody and wash the plate three times using a plate washer;
[0064] (2) Dilute Streptavidin-PE using Assay Buffer according to the instructions;
[0065] (3) Add 50 μL of diluted Streptavidin-PE to each well, cover with sealing film, place on a plate shaker at 850 rpm, protect from light, incubate at room temperature for 10 min;
[0066] (4) Wash three times using a plate washer;
[0067] (5) Add 125 μL of Assay Buffer to each well to resuspend, cover with sealing film, and place on a plate shaker at 850 rpm at room temperature, protected from light, and shake for 30 seconds;
[0068] (6) The results were sent to the calibrated BioPlex 200 machine for reading.
[0069] 1.4 Data Results
[0070] After the samples and standards are tested by the BioPlex 200 detector, the fluorescence obtained is automatically calculated and optimized by the software to form an Excel format output file.
[0071] 1.5 Screening biomarkers
[0072] Based on the expression levels of the 40 chemokines or cytokines detected in these four populations, chemokines or cytokines with differential expression between healthy controls and tuberculosis-infected patients were screened out: the expression of MIG / CXCL9, IP-10 / CXCL10, and MCP-2 / CCL8 after tuberculosis-specific antigen stimulation showed significant differences between the two groups and can be used as diagnostic biomarkers (see Figure 1).
[0073] The 40 cytokines and chemokines are as follows:
[0074] CCL21, CXCL13, CCL27, CXCL5, CCL24, CCL26, CCL11, CX3CL1, CXCL6, GMCSF, CXCL1, CXCL2, CCL1, CXCL11, IFN-r, IL-1B, IL-2, IL-4, IL-6, CXCL 8. IL-10, IL-16, CXCL10, CCL2, CCL8, CCL7, CCL13, CCL22, MIF, CXCL9, CCL3, CCL15, CCL20, CCL19, CCL23, CXCL16, CXCL12, CCL25, CCL17, TNFa.
[0075] Example 2 Analysis of the diagnostic value of biomarkers and compositions for tuberculosis infection
[0076] To further analyze the diagnostic value of these cytokines or chemokines, we first performed a receiver operating characteristic (ROC) analysis. The area under the curve (AUCs) in the ROC analysis was used to evaluate the ability of a single chemokine or cytokine to discriminate between the two groups. Larger AUCs indicate better diagnostic efficacy for that chemokine.
[0077] 2.1 Analysis of the differential diagnostic value of MIG / CXCL9
[0078] The AUC of chemokine MIG / CXCL9 for differential diagnosis of tuberculosis infection was 0.983 (see Figure 2 ), with a diagnostic sensitivity of 93.55% and a specificity of 100.00%.
[0079] 2.2 Analysis of the differential diagnostic value of IP-10 / CXCL10
[0080] The AUC of IP-10 / CXCL10 for differential diagnosis of tuberculosis infection was 0.968 (see Figure 3 ), with a diagnostic sensitivity of 90.32% and a specificity of 100.00%.
[0081] 2.3 Analysis of the differential diagnostic value of MCP-2 / CCL8
[0082] The AUC of MCP-2 / CCL8 for differential diagnosis of tuberculosis infection was 0.933 (see Figure 4 ), with a diagnostic sensitivity of 82.26% and a specificity of 95.00%.
[0083] 2.4 Chemokine combination of IP-10 / CXCL10 and MCP-2 / CCL8
[0084] The AUC of the combination of chemokines IP-10 / CXCL10 and MCP-2 / CCL8 for distinguishing tuberculosis infection was calculated using a logistic stepwise regression model, which was 0.952 (see Figure 5). The overall diagnostic sensitivity was 88.71% and the specificity was 100.00%, both of which had high diagnostic efficacy.
[0085] The chemokines differentially expressed in cell culture plasma between healthy controls and tuberculosis patients were screened. The screened chemokines were used as diagnostic markers and detected using liquid phase chip technology. This method can be used for rapid detection of tuberculosis infection, has high diagnostic efficacy, is relatively simple to operate, and can improve the detection rate of tuberculosis infection (see Table 1).
[0086] Table 1: Analysis of the diagnostic value of chemokines
[0087] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various changes can be made to the technical solutions of the present invention. These simple variations all fall within the scope of protection of the present invention.
[0088] It should also be noted that the various specific technical features and steps described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will no longer separately describe various possible combinations.
[0089] In addition, the various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.
Claims
1. A biomarker for diagnosing tuberculosis infection, wherein the marker is one or more of CXCL9, CXCL10, and CCL8. When the expression level of one or more of CXCL9, CXCL10, and CCL8 is higher than the critical value of the expression level of the factor, the subject can be diagnosed as a person infected with Mycobacterium tuberculosis; when the expression level of one or more of CXCL9, CXCL10, and CCL8 is lower than or equal to the critical value of the expression level of the factor, the subject can be diagnosed as a person infected with non-tuberculous mycobacteria.
2. The biomarker for diagnosing tuberculosis infection according to claim 1, characterized in that: The critical values (pg / mL) of the expression levels of CXCL9, CXCL10, and CCL8 are 258.78, 267.53, and 30.31, respectively.
3. The biomarker for diagnosing tuberculosis infection according to claim 1, characterized in that: The tuberculosis infection is an infection caused by the presence of the pathogen Mycobacterium tuberculosis.
4. The biomarker for diagnosing tuberculosis infection according to claim 1, characterized in that: The tuberculosis infection includes: primary infection, secondary infection, and extrapulmonary infection.
5. A method for evaluating the efficacy of a treatment for tuberculosis infection, comprising: S1 Obtain a test biological sample from a tuberculosis infected person; S2 detects the levels of biomarkers such as CXCL9, CXCL10, and CCL8; S3 compares the content detection results of CXCL9, CXCL10, and CCL8 with their corresponding critical values. When the expression levels of one or more of CXCL9, CXCL10, CCL8, and the combination of CXCL10 and CCL8 are respectively higher than the critical value of the factor, the subject can be diagnosed as being infected with Mycobacterium tuberculosis, indicating that the anti-tuberculosis infection treatment of the subject is poor or ineffective; when one or more of CXCL9, CXCL10, CCL8, and the combination of CXCL10 and CCL8 are respectively lower than or equal to the critical value of the factor, the subject can be diagnosed as being infected with non-tuberculous mycobacteria, indicating that the anti-tuberculosis infection treatment of the subject is effective.
6. A kit for diagnosing tuberculosis infection, the kit comprising reagents for detecting biomarkers, instructions, etc., wherein the markers are one or more of CXCL9, CXCL10, and CCL8.
7. Use of a biomarker in preparing a preparation for diagnosing tuberculosis infection, wherein the biomarker is one or more of CXCL9, CXCL10, and CCL8. When the expression level of one or more of CXCL9, CXCL10, and CCL8 is higher than the critical value of the expression level of the factor, the subject can be diagnosed as being infected with Mycobacterium tuberculosis; when the expression level of one or more of CXCL9, CXCL10, and CCL8 is lower than or equal to the critical value of the expression level of the factor, the subject can be diagnosed as being infected with non-tuberculous mycobacteria.
Citation Information
Patent Citations
Biomarker for diagnosing mycobacterium tuberculosis infection and related kit
CN106501530A
biomarkers
CN113748342A
Application of CXCL14 as biomarker in tuberculosis diagnosis
CN114563576A
Pump cap
KR1020210124741A
Anti-CXCL9, Anti-CXCL10, Anti-CXCL11, Anti-CXCL13, Anti-CXCR3 and Anti-CXCR5 agents for inflammatory disorders
US20120264645A1
Cited By
Biomarker for diagnosing short-term and long-term tuberculosis infection
CN119780441A
